Paul Aisen

Last updated

Paul Stephen Aisen is an American physician and medical researcher. He started his career as a rheumatologist and then made Alzheimer's disease his focus.

Contents

As of 2015 he was on the faculty of the Keck School of Medicine of USC and his offices were in San Diego. [1]

Career

Aisen did his undergraduate work in biochemistry and molecular biology at Harvard and obtained his medical degree from Columbia University. He did his residency at Case Western Reserve University and at Mount Sinai Medical Center in New York, and trained further through a fellowship in rheumatology at New York University. He has a private practice as a GP and rheumatologist in New York, then joined the faculty of Mount Sinai in 1994. He was recruited to the Georgetown University School of Medicine in 1999 in neurology and medicine and began focusing his practice and research on Alzheimer's disease there. [2]

In 2007 Aisen was recruited to University of California San Diego to run the Alzheimer's Disease Cooperative Study, which UCSD had established in 1991 and coordinates studies on Alzheimer's disease drugs like solanezumab. [3] He left UCSD in 2015 because he was unhappy with the level of support that UCSD was providing him and due to USC's offer. [4] UCSD and USC ended up in litigation over control of the ca. $100 million program and its research data, which involved six ongoing clinical trials and data collected on thousands of clinical trial subjects. [5] [6] Part of the dispute arose because Aisen's lab had uploaded the data from the ADCS onto Amazon Cloud servers and would not give the passwords to UCSD officials. [3] USC rented space for Aisen in a San Diego office park, where Keck's Alzheimer's Therapeutic Research Institute is located under Aisen's direction. [1] [7] Some aspects of data management were temporarily settled in 2016; [8] and a settlement was reached in 2019, with USC to pay UCD $50 million compensation and make a public statement that is actions "did not align with the standards of ethics and integrity which USC expects of all its faculty, administrators, and staff." [9]

Aisen has been a strong proponent of the amyloid hypothesis and as of 2017 believed that earlier intervention with drugs against amyloid might show more efficacy than interventions when the disease process is well underway, and has helped initiate large trials to test ways to prevent Alzheimer's disease. [10] [11]

He has served as a consultant or advisor for pharmaceutical companies Eli Lilly [3] [12] and Janssen, [13] smaller biotech companies exploring alternative approaches to AD like Anavex Life Sciences, [14] Proclara, [15] CohBar, [16] and Neurophage, [17] as well as nonprofits like ACT-AD. [18] He is a principal investigator in the Alzheimer's Disease Neuroimaging Initiative. [19]

Recognition

In November 2018 Expertscape recognized Aisen as one of the world's top-ranked experts in Alzheimer's disease. [20] He has an h-index of 107 according to Semantic Scholar. [21]

Publications

Related Research Articles

The Keck School of Medicine of the University of Southern California teaches and trains physicians, biomedical scientists and other healthcare professionals, conducts medical research, and treats patients. Founded in 1885, it is the second oldest medical school in California after the UCSF School of Medicine.

<span class="mw-page-title-main">Tauopathy</span> Medical condition

Tauopathies are a class of neurodegenerative diseases characterized by the aggregation of abnormal tau protein. Hyperphosphorylation of tau proteins causes them to dissociate from microtubules and form insoluble aggregates called neurofibrillary tangles. Various neuropathologic phenotypes have been described based on the anatomical regions and cell types involved as well as the unique tau isoforms making up these deposits. The designation 'primary tauopathy' is assigned to disorders where the predominant feature is the deposition of tau protein. Alternatively, diseases exhibiting tau pathologies attributed to different and varied underlying causes are termed 'secondary tauopathies'. Some neuropathologic phenotypes involving tau protein are Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.

<span class="mw-page-title-main">University of California, San Diego School of Medicine</span> Medical school of UC San Diego

The University of California, San Diego School of Medicine is the graduate medical school of the University of California, San Diego, a public land-grant research university in La Jolla, California. It was the third medical school in the University of California system, after those established at UCSF and UCLA, and is the only medical school in the San Diego metropolitan area. It is closely affiliated with the medical centers that are part of UC San Diego Health.

Bart De Strooper is a Belgian molecular biologist and professor at Vlaams Instituut voor Biotechnologie and KU Leuven and the UK Dementia Research Institute and University College London, UK. De Strooper's research seeks to translate genetic data into the identification and treatment of neurodegenerative diseases and treatments. interest are the secretases, proteases which cleave the amyloid precursor protein (APP), resulting in amyloid peptides.

<span class="mw-page-title-main">Alzheimer's disease</span> Progressive neurodegenerative disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to twelve years.

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

<span class="mw-page-title-main">Larry Squire</span> American psychologist

Larry Ryan Squire is an American psychiatrist and neuroscientist. He is a professor of psychiatry, neurosciences, and psychology at the University of California, San Diego, and a Senior Research Career Scientist at the Veterans Affairs Medical Center, San Diego. He is a leading investigator of the neurological bases of memory, which he studies using animal models and human patients with memory impairment.

Samuel E. Gandy, is a neurologist, cell biologist, Alzheimer's disease (AD) researcher and expert in the metabolism of the sticky substance called amyloid that clogs the brain in patients with Alzheimer's. His team discovered the first drugs that could lower the formation of amyloid.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

The biomarkers of Alzheimer's disease are neurochemical indicators used to assess the risk or presence of the disease. The biomarkers can be used to diagnose Alzheimer's disease (AD) in a very early stage, but they also provide objective and reliable measures of disease progress. It is imperative to diagnose AD disease as soon as possible, because neuropathologic changes of AD precede the symptoms by years. It is well known that amyloid beta (Aβ) is a good indicator of AD disease, which has facilitated doctors to accurately pre-diagnose cases of AD. When Aβ peptide is released by proteolytic cleavage of amyloid-beta precursor protein, some Aβ peptides that are solubilized are detected in CSF and blood plasma which makes AB peptides a promising candidate for biological markers. It has been shown that the amyloid beta biomarker shows 80% or above sensitivity and specificity, in distinguishing AD from dementia. It is believed that amyloid beta as a biomarker will provide a future for diagnosis of AD and eventually treatment of AD.

Anders Martin Dale is a prominent neuroscientist and professor of radiology, neurosciences, psychiatry, and cognitive science at the University of California, San Diego (UCSD), and is one of the world's leading developers of sophisticated computational neuroimaging techniques. He is the founding Director of the Center for Multimodal Imaging Genetics (CMIG) at UCSD.

Florbetaben, sold under the brand name Neuraceq, is a diagnostic radiotracer developed for routine clinical application to visualize β-amyloid plaques in the brain. It is a fluorine-18 (18F)-labeled stilbene derivative.

<span class="mw-page-title-main">Don W. Cleveland</span> American cancer biologist and neurobiologist

Don W. Cleveland is an American cancer biologist and neurobiologist.

<span class="mw-page-title-main">Philip Scheltens</span> Dutch professor of neurology

Philip Scheltens is a Dutch professor of neurology and founder of the Alzheimer Centre, Amsterdam University Medical Centers, location VUmc in Amsterdam.

<span class="mw-page-title-main">Giulio Maria Pasinetti</span>

Giulio Maria Pasinetti is the Program Director of the Center on Molecular Integrative Neuroresilience and is the Saunders Family Chair in Neurology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Pasinetti is a Professor of Neurology, Psychiatry, Neuroscience, and Geriatrics and Palliative Medicine at ISMMS.

The Alzheimer's Disease Cooperative Study (ADCS) was founded at University of California San Diego in 1991 and coordinates clinical trials of candidate treatments for Alzheimer's disease.

<span class="mw-page-title-main">David M. Holtzman</span> Medical researcher

David M. Holtzman is an American physician-scientist known for his work exploring the biological mechanisms underlying neurodegeneration, with a focus on Alzheimer's disease. Holtzman is former Chair of the Department of Neurology, Scientific Director of the Hope Center for Neurological Disorders, and associate director of the Knight Alzheimer's Disease Research Center at Washington University School of Medicine in St. Louis, Missouri. Holtzman's lab is known for examining how apoE4 contributes to Alzheimer's disease as well as how sleep modulates amyloid beta in the brain. His work has also examined the contributions of microglia to AD pathology.

Nicole Schupf is an American epidemiologist and neuroscientist who is Professor of Epidemiology in Neurology, Psychiatry, the Gertrude H. Sergievsky Center, and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Faculty of Medicine. She studies aging and Alzheimer's disease in individuals with Down syndrome.

Jennifer J. Manly is an American neuropsychologist. She is a Professor of Neuropsychology in Neurology at the Gertrude H. Sergievsky Center and the Taub Institute for Research in Aging and Alzheimer's Disease at Columbia University. Manly studies how race, culture, socioeconomic status, and education influence the risk of cognitive decline in aging.

Howard H Feldman is a professor of neurosciences at the University of California, San Diego (UCSD). He was appointed director of the Alzheimer's Disease Cooperative Study (ADCS) in April 2016, a national grant-funded network and coordinating center that was established in 1991. He holds the Epstein Family Chancellor’s Chair in Alzheimer’s Disease Research at UC San Diego. Prior to joining UC San Diego, he was on faculty at University of British Columbia where he served as the Head of the Division of Neurology, the Director of the Alzheimer’s and Related Disorders Clinic and the Executive Associate Dean for Research for the Faculty of Medicine.

References

  1. 1 2 Fikes, Bradley J. (2 August 2015). "Next steps for scientist in eye of UCSD-USC Alzheimer's spat". San Diego Tribune.
  2. ↑ "Faculty profile: Paul Stephen Aisen". Keck School of Medicine of USC. Retrieved 15 June 2017.
  3. 1 2 3 Garde, Damian (August 5, 2015). "Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute". FierceBiotech.
  4. ↑ Fikes, Bradley J. (5 July 2015). "UC San Diego sues USC and scientist, alleging conspiracy to take funding, data". Los Angeles Times.
  5. ↑ Check Hayden, Erika (16 July 2015). "Alzheimer's data lawsuit is sign of growing tensions". Nature. 523 (7560): 265. doi: 10.1038/nature.2015.17932 .
  6. ↑ Basken, Paul (23 July 2015). "Grant Dispute Throws an Unwritten Rule of Academic Poaching Out the Window". The Chronicle of Higher Education.
  7. ↑ Wang, Shirley S.; Loftus, Peter (14 October 2015). "Alzheimer's Research Effort Is Ensnared in Legal Dispute". Wall Street Journal.
  8. ↑ Potter, Matt (January 11, 2016). "Deal gives UCSD "read only" rights to Alzheimer's data". San Diego Reader.
  9. ↑ "Settlement Reached Between UCSD and USC, Paul Aisen". ALZForum. 5 July 2019. Retrieved 21 November 2020.
  10. ↑ Elie, Dolgin (16 February 2017). "The new offensive on Alzheimer's disease: Stop it before it starts". Newsweek.
  11. ↑ Sperling, RA; Rentz, DM; Johnson, KA; Karlawish, J; Donohue, M; Salmon, DP; Aisen, P (19 March 2014). "The A4 study: stopping AD before symptoms begin?". Science Translational Medicine. 6 (228): 228fs13. doi:10.1126/scitranslmed.3007941. PMC   4049292 . PMID   24648338.
  12. ↑ Ornstein, Charles; Groeger, Groeger; Tigas, Mike; Grochowski Jones, Ryann. "Dollars for Docs: Paul Aisen". ProPublica.
  13. ↑ Osborne, Randy (January 17, 2017). "WashU early AD initiative could yield broader clues". BioWorld Today.
  14. ↑ "Scientific Advisory Board". Anavex. Retrieved 15 June 2017.
  15. ↑ "Leadership - SAB - Paul Aisen". Proclara Biosciences. Retrieved 15 June 2017.
  16. ↑ "Paul Aisen, M.D. – Consultant, Alzheimer's Disease". CohBar. Retrieved 15 June 2017.
  17. ↑ "Scientific Advisory Board". Neurophage Pharmaceuticals. Retrieved 15 June 2017.
  18. ↑ "Science Advisory Board". ACT-AD. Retrieved 15 June 2017.
  19. ↑ "Principal Investigators". ADNI. Retrieved 15 June 2017.
  20. ↑ "Expertscape: Alzheimer Disease, November 2018". expertscape.com. November 2018. Retrieved 2018-11-15.
  21. ↑ "P. Aisen". Semantic Scholar . Retrieved 2 December 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.